

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims.

Listing of claims

1-20. (Canceled)

21. (Previously presented) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) amino acid residues +1 to +84 of SEQ ID NO:2;
- (b) amino acid residues +2 to +84 of SEQ ID NO:2;
- (c) amino acid residues +17 to +84 of SEQ ID NO:2;
- (d) amino acid residues +18 to +84 of SEQ ID NO:2;
- (e) amino acid residues +19 to +84 of SEQ ID NO:2;
- (f) amino acid residues +20 to +84 of SEQ ID NO:2;
- (g) amino acid residues +21 to +84 of SEQ ID NO:2; and
- (h) amino acid residues +22 to +84 of SEQ ID NO:2.

22. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (a).

23. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (b).

24. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (c).

25. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (d).

26. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (e).

27. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (f).

28. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (g).
29. (Previously presented) The isolated polypeptide of claim 21, which comprises amino acid sequence (h).
30. (Previously presented) The isolated polypeptide of claim 21, which further comprises a heterologous amino acid sequence.
31. (Previously presented) The isolated polypeptide of claim 30 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin.
32. (Previously presented) The isolated polypeptide of claim 21, which is glycosylated.
33. (Previously presented) The isolated polypeptide of claim 21 produced by a method comprising:
- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 21 under conditions that result in expression of said polypeptide; and
 - (b) recovering the polypeptide.
34. (Previously presented) A composition comprising the isolated polypeptide of claim 21 and a pharmaceutically acceptable carrier.
35. (Previously presented) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209643;
 - (b) the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209643; and
 - (c) the amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 209643.

36. (Previously presented) The isolated polypeptide of claim 35 which comprises amino acid sequence (a).
37. (Previously presented) The isolated polypeptide of claim 35 which comprises amino acid sequence (b).
38. (Previously presented) The isolated polypeptide of claim 35 which comprises amino acid sequence (c).
39. (Previously presented) The isolated polypeptide of claim 35, which further comprises a heterologous amino acid sequence.
40. (Previously presented) The isolated polypeptide of claim 39 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin.
41. (Previously presented) The isolated polypeptide of claim 35, which is glycosylated.
42. (Previously presented) The isolated polypeptide of claim 35 produced by a method comprising:
- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 35 under conditions that result in expression of said polypeptide; and
 - (b) recovering the polypeptide.
43. (Previously presented) A composition comprising the isolated polypeptide of claim 35 and a pharmaceutically acceptable carrier.
44. (Currently amended) An isolated polypeptide comprising a first amino acid sequence at least 90% identical to a second amino acid sequence selected from the group consisting of:
- (a) amino acid residues +1 to +84 of SEQ ID NO:2;
 - (b) amino acid residues +2 to +84 of SEQ ID NO:2;
 - (c) amino acid residues +17 to +84 of SEQ ID NO:2;
 - (d) amino acid residues +18 to +84 of SEQ ID NO:2;
 - (e) amino acid residues +19 to +84 of SEQ ID NO:2;

- (f) amino acid residues +20 to +84 of SEQ ID NO:2;
- (g) amino acid residues +21 to +84 of SEQ ID NO:2; and
- (h) amino acid residues +22 to +84 of SEQ ID NO:2;

wherein said polypeptide ~~has chemokine α -6 activity~~ is chemotactic for leukocytes.

45. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (a).

46. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (a).

47. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (b).

48. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (b).

49. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (c).

50. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (c).

51. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (d).

52. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (d).

53. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (e).

54. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (e).

55. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (f).

56. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (f).

57. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (g).

58. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (g).

59. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (h).

60. (Previously presented) The isolated polypeptide of claim 44 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (h).

61. (Previously presented) The isolated polypeptide of claim 44, which further comprises a heterologous amino acid sequence.

62. (Previously presented) The isolated polypeptide of claim 61 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin.

63. (Previously presented) The isolated polypeptide of claim 44, which is glycosylated.

64. (Previously presented) The isolated polypeptide of claim 44 produced by a method comprising:

- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 44 under conditions that result in expression of said polypeptide; and
- (b) recovering the polypeptide.

65. (Previously presented) A composition comprising the isolated polypeptide of claim 44 and a pharmaceutically acceptable carrier.

66. (Currently amended) An isolated polypeptide comprising a first amino acid sequence at least 90% identical to a second amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of the full-length polypeptide encoded by the cDNA in ATCC Deposit No. 209643;
- (b) the amino acid sequence of the full-length polypeptide, excluding the N-terminal methionine residue, encoded by the cDNA in ATCC Deposit No. 209643; and
- (c) the amino acid sequence of the mature polypeptide encoded by the cDNA in ATCC Deposit No. 209643;

wherein said polypeptide ~~has chemokine α -6 activity~~ is chemotactic for leukocytes.

67. (Previously presented) The isolated polypeptide of claim 66 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (a).

68. (Previously presented) The isolated polypeptide of claim 66 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (a).

69. (Previously presented) The isolated polypeptide of claim 66 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (b).

70. (Previously presented) The isolated polypeptide of claim 66 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (b).

71. (Previously presented) The isolated polypeptide of claim 66 wherein said first amino acid sequence is at least 90% identical to said second amino acid sequence (c).

72. (Previously presented) The isolated polypeptide of claim 66 wherein said first amino acid sequence is at least 95% identical to said second amino acid sequence (c).

73. (Previously presented) The isolated polypeptide of claim 66, which further comprises a heterologous amino acid sequence.

74. (Previously presented) The isolated polypeptide of claim 73 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin.

75. (Previously presented) The isolated polypeptide of claim 66, which is glycosylated.

76. (Previously presented) The isolated polypeptide of claim 66 produced by a method comprising:

- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 66 under conditions that result in expression of said polypeptide; and
- (b) recovering the polypeptide.

77. (Previously presented) A composition comprising the isolated polypeptide of claim 66 and a pharmaceutically acceptable carrier.

78. (Currently amended) An isolated polypeptide ~~comprising~~ consisting of a fragment of the polypeptide of SEQ ID NO:2, wherein said fragment has an amino acid sequence selected from the group consisting of:

- (a) amino acid residues +26 to +34 of SEQ ID NO:2;
- (b) amino acid residues +36 to +45 of SEQ ID NO:2;
- (c) amino acid residues +58 to +66 of SEQ ID NO:2; and
- (d) amino acid residues +77 to +84 of SEQ ID NO:2.

79. (Currently amended) The isolated polypeptide of claim 78 ~~which comprises wherein the~~ amino acid sequence is (a).

80. (Currently amended) The isolated polypeptide of claim 78 ~~which comprises wherein the~~ amino acid sequence is (b).

81. (Currently amended) The isolated polypeptide of claim 78 ~~which comprises wherein the~~ amino acid sequence is (c).

82. (Currently amended) The isolated polypeptide of claim 78 ~~which comprises wherein the~~ amino acid sequence is (d).

83. (Currently amended) The isolated polypeptide of claim 78, which ~~further comprises~~ is fused to a heterologous amino acid sequence.

84. (Previously presented) The isolated polypeptide of claim 83 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin.

85. (Previously presented) The isolated polypeptide of claim 78, which is glycosylated.

86. (Previously presented) The isolated polypeptide of claim 78 produced by a method comprising:

- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 78 under conditions that result in expression of said polypeptide; and
- (b) recovering the polypeptide.

87. (Previously presented) A composition comprising the isolated polypeptide of claim 78 and a pharmaceutically acceptable carrier.

88. (Previously presented) An isolated polypeptide consisting of at least 30 contiguous amino acid residues of SEQ ID NO:2.

89. (Previously presented) The isolated polypeptide of claim 88, which consists of at least 50 contiguous amino acid residues of SEQ ID NO:2.

90. (Previously presented) The isolated polypeptide of claim 88, which is fused to a heterologous amino acid sequence.

91. (Previously presented) The isolated polypeptide of claim 90 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin

92. (Previously presented) The isolated polypeptide of claim 88, which is glycosylated

93. (Previously presented) The isolated polypeptide of claim 88 produced by a method comprising:

- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 88 under conditions that result in expression of said polypeptide; and
- (b) recovering the polypeptide.

94. (Previously presented) A composition comprising the isolated polypeptide of claim 88 and a pharmaceutically acceptable carrier.

95. (Previously presented) An isolated polypeptide consisting of at least 30 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209643.

96. (Previously presented) The isolated polypeptide of claim 95, which consists of at least 50 contiguous amino acid residues encoded by the cDNA in ATCC Deposit No. 209643.

97. (Previously presented) The isolated polypeptide of claim 95, which is fused to a heterologous amino acid sequence.

98. (Previously presented) The isolated polypeptide of claim 97 wherein said heterologous amino acid sequence is the Fc domain of immunoglobulin.

99. (Previously presented) The isolated polypeptide of claim 95, which is glycosylated.

100. (Previously presented) The isolated polypeptide of claim 95 produced by a method comprising:

- (a) culturing a cell comprising a recombinant polynucleotide encoding the polypeptide of claim 95 under conditions that result in expression of said polypeptide; and
- (b) recovering the polypeptide.

101. (Previously presented) A composition comprising the isolated polypeptide of claim 95 and a pharmaceutically acceptable carrier.

102-111. (Canceled)